Louisiana State Employees Retirement System
PensionPosition in TGTX — Tg Therapeutics, Inc.
CIK 1537191
BATON ROUGE, LA
Position in TGTX
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$3,175,532
+$1,172,366 QoQ
Shares Held
57,800
-4.1% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#10
of 116 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TGTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Louisiana State Employees Retirement System holds $83,092,965 across 30 Biotechnology names. TGTX ranks #12 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
29,300 | $14,554,189 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11,700 | $7,295,418 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
131,900 | $4,667,941 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
18,400 | $4,433,848 | |
| 5 | KRYS |
Krystal Biotech, Inc.
|
11,500 | $4,274,205 | |
| 6 | EXEL |
Exelixis, Inc.
|
73,600 | $4,004,576 | |
| 7 | CORT |
Corcept Therapeutics Inc
|
41,900 | $3,643,205 | |
| 8 | CYTK |
Cytokinetics Inc
|
39,700 | $3,382,043 |
All Filings in TGTX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,175,532 | 57,800 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $2,003,166 | 60,300 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $1,857,163 | 62,300 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $2,254,200 | 62,400 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $2,281,766 | 63,400 | Shares | Sole | 2025-07-23 | |
| 2025-03-31 | $2,480,147 | 62,900 | Shares | Sole | 2025-05-01 | |
| 2024-12-31 | $1,941,450 | 64,500 | Shares | Sole | 2025-01-29 | |
| 2024-09-30 | $1,508,655 | 64,500 | Shares | Sole | 2024-10-23 | |
| No filing history on record for this holder in this stock. | ||||||